Autism – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Autism
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

This latest Pharmaceutical and Healthcare disease pipeline guide Autism
– Pipeline Review, H1 2019, provides an overview of the Autism (Central
Nervous System) pipeline landscape.

The report provides comprehensive information on the therapeutics under
development for Autism (Central Nervous System), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key
players involved in therapeutic development for Autism and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Phase III, Phase II, Phase
I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 8,
6, 1, 20, 2 and 2 respectively. Similarly, the Universities portfolio in
Preclinical stages comprises 2 molecules, respectively.

The guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive
advantage. The guide is built using data and information sourced from
the researcher’s proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites
and industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured
on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Autism (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Autism (Central
  Nervous System) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Autism (Central
  Nervous System) therapeutics and enlists all their major and minor
  projects.
• The pipeline guide evaluates Autism (Central Nervous System)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Autism (Central Nervous System)

Reasons to buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Autism (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Autism (Central Nervous System) pipeline depth and focus of Indication
  therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Autism – Overview
• Autism – Therapeutics Development
• Autism – Therapeutics Assessment
• Autism – Companies Involved in Therapeutics Development
• Autism – Drug Profiles
• Autism – Dormant Projects
• Autism – Discontinued Products
• Autism – Product Development Milestones

Companies Mentioned

• 4D Pharma PLC
• AgeneBio Inc
• AMO Pharma Ltd
• APeT Holding BV
• BioHealthonomics Inc
• BrainStorm Cell Therapeutics Inc
• Curemark LLC
• Epigen Biosciences Inc
• Evgen Pharma Plc
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• GW Pharmaceuticals Plc
• Immuron Ltd
• Insys Therapeutics Inc
• Intra-Cellular Therapies Inc
• Johnson & Johnson
• Leading BioSciences Inc
• Ovensa Inc
• Panorama Research Inc
• Sosei Heptares
• Sumitomo Dainippon Pharma Co Ltd
• Zynerba Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3u27wd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related
Topics: Central
Nervous System Drugs